Applied Biosystems, a division of Life Technologies (NASDAQ:LIFE), today announced that scientists at Jupiter Environmental Laboratories in Florida are using a mass spectrometry solution to support the environmental restoration of the once pristine waterways of the Florida Everglades. These scientists are using this technology as part of their support of the Comprehensive Everglades Restoration Plan, a government-sponsored effort to restore, protect and preserve the water resources of central and southern Florida.
One of the key projects associated with this effort calls for reclaiming thousands of acres of citrus groves and sugar farms, and restoring the natural waterways of the Everglades. This effort requires the identification and elimination of a wide variety of pesticides and other contaminants. To address this challenge, the team at Jupiter Laboratories is using the SCIEX QTRAP® 5500 System, a next-generation mass spectrometer, to provide information that will enable environmental engineers to make more informed decisions regarding how to dismantle canals, transfer land, and restore natural flood plains. This technology was developed by the jointventure partnership of Applied Biosystems and MDS Analytical Technologies, a business unit of MDS Inc. (TSX:MDS) (NYSE:MDZ)
"This restoration project is critical to the long-term survival of the Everglades ecosystem," said EdDabrea, Chief Scientist at Jupiter Environmental Laboratories. "We felt it was important to utilize the most advanced scientific approach to provide the highest-quality data for identifying the various types of contamination that need to be addressed."
The SCIEX QTRAP 5500 System is a unique mass spectrometer from Applied Biosystems/MDS Analytical Technologies that enables scientists to identify and confirm results in a single analysis. It features a combination of sensitivity, scanning speed and capacity that enables the analysis of more than 1,000 chemicals in a single test. This system augments the speed of obtaining results from weeks using other technologies, to typically less than two days.
"The Everglades project exemplifies how environmental scientists are applying mass spectrometry to address a serious issue that requires powerful analytical scientific tools," said Laura Lauman, President of the Mass Spectrometry Systems Division of Life Technologies. "Our customers have a tremendous responsibility that directly impacts human health and overall well-being. We're providing them with technologies that enable them to do their work as effectively as possible." Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems is a leading provider of mass spectrometry solutions through its joint venture with MDS Analytical Technologies. Applied Biosystems, along with Invitrogen - a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics - is part of Life Technologies. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.
For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.
About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative instrument systems to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Applied Biosystems, along with Invitrogen - a leading provider of platform independent, essential life science technologies for disease and drug research, bioproduction and diagnostics - is part of Life Technologies. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world. For more information, please visit: www.appliedbiosystems.com and www.invitrogen.com.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc. For more information on how we are making a difference please visit our website: www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.